Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inotuzumab Ozogamicin + Low-Intensity Chemotherapy in ALL
NCT01371630Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Aug 2011
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of inotuzumab ozogamicin in acute lymphoblastic leukemia (ALL), Burkitt lymphoma (BL), high grade B-cell lymphoma (HGBCL), sponsored by University of Texas MD Anderson Cancer Center. Started Aug 2011; status: recruiting.
02
Drugs
inotuzumab ozogamicin
03
Conditions
acute lymphoblastic leukemia (ALL)Burkitt lymphoma (BL)high grade B-cell lymphoma (HGBCL)
Beyond the preview
Go deeper on NCT01371630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01371630.